Mosliciguat represents a novel therapeutic class targeting pulmonary hypertension. It functions as a soluble guanylate cyclase activator, enhancing the body’s nitric oxide pathway to relax blood vessels and reduce arterial pressure. Administered orally, this investigational drug is designed for patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. By improving exercise capacity and slowing disease progression, mosliciguat offers renewed hope for those with limited existing treatment options.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends